A Phase 3 interventional study of Rivaroxaban in Arthritis, Osteoarthritis, Knee and Osteoarthritis, Hip, sponsored by Ortho-McNeil Janssen Scientific Affairs, LLC. Completed at 5 sites in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2017-03-17.
Sponsored by Ortho-McNeil Janssen Scientific Affairs, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Arthritis by Johnson & Johnson — none open to participants now, none under way, none of them phase 3. Arthritis · Johnson & Johnson.
Among the 11 studies in Arthritis by Johnson & Johnson, this one is the only one that started in 2010, is one of 3 in phase 3, and was the 9th registered.
843 studies on the registry are indexed under Arthritis; 118 are open to participants now.
Browse Arthritis studies →None of the 11 studies in Arthritis by Johnson & Johnson is open now. The open studies under Arthritis, anywhere →
Of the 78 Arthritis studies recruiting now, 41 (53%) set no upper age limit and 20 (26%) stop at 75 or younger; 16 take children under 18; 15 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 1 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 56 is below the median of 97 across 599 interventional studies indexed under Arthritis.
Median enrollment 341 across the 8 interventional studies, 140 across the 3 observational. Of the 10 that completed or were terminated, 4 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Ortho-McNeil Janssen Scientific Affairs, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Ortho-McNeil Janssen Scientific Affairs, LLC is the lead sponsor of 16 studies on the registry; none are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Arthritis by Johnson & Johnson, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study will describe the short-term effects the study drug, rivaroxaban, has on the body when a patient is switched from enoxaparin injection (by needle) to oral rivaroxaban (by mouth) for the prevention of blood clotting in the veins after elective total hip or total knee replacement surgery. After providing written informed consent, screening procedures will be completed to assess eligibility. After enrollment, all patients will be switched from enoxaparin to rivaroxaban. Blood samples for the short-term effects of rivaroxaban will be taken at various times while in the subacute unit. At the time of discharge, if the study doctor feels it is appropriate, an adequate supply of rivaroxaban will be provided to complete the full course of therapy. Upon completion of rivaroxaban therapy, all patients will be required to have final study procedures performed. Safety evaluations at the final visit will include clinical blood laboratory tests, a physical examination, urine pregnancy test (if applicable), recording of any adverse events including details regarding any bleeding episodes or blood clot events, and assessment of the surgical wound. All patients will return any unused study medication and study participation will be complete.
The study medication, rivaroxaban, is an oral (by mouth) medication. Rivaroxaban directly inhibits one of the clotting mechanisms in the blood that is involved in the formation of blood clots in the veins in the body. The ability to inhibit blood clotting will be measured. Rivaroxaban is currently approved in the European Union by the European Medicines Agency (EMEA) for the prevention of blood clots in veins in orthopedic (bone) surgical patients who have had elective total joint (hip or knee) replacement. It is currently under review by the Food and Drug Administration (FDA) in the United States for this same indication. Enoxaparin is a medication that is injected into the fat tissue under the skin and is approved by the FDA for the treatment and prevention of blood clot formation in the veins. The goal of the study is to describe the short-term effects that the study drug has on the body when a patient is switched from enoxaparin to rivaroxaban. The study hypothesis, or theory, is that when switched from enoxaparin to rivaroxaban the ability of the body to inhibit blood clotting activity will continue. This is an open-label study which means that all persons involved in the study will know what study drug is being given to them. It is a single-arm study which means that all patients will be administered the same study medication, rivaroxaban. The study will be conducted at large orthopedic centers in the United States. All patients will have had elective total hip or total knee replacement surgery. While in the hospital, eligible patients will have been receiving enoxaparin either 30 mg twice a day or 40 mg once daily. Upon discharge from the hospital all eligible patients will require a stay in a subacute unit and continuing medication for blood clot prevention. After providing written informed consent, patients will have screening procedures completed to determine eligibility. Safety evaluations at the screening procedure will include a physical examination, vital signs, and clinical blood laboratory tests. Women, who are able to bear children, will also have a screening blood pregnancy test performed. A negative pregnancy test is needed to be in the study. Just before receiving the first dose of rivaroxaban, 10 mg, blood sampling for the short-term effects of rivaroxaban will begin and continue at various times. All patients will receive 10 mg of rivaroxaban daily. In addition, the study doctor will do an assessment of the surgical wound. At the time of discharge from the subacute unit, if the study doctor feels it is appropriate, an adequate supply of rivaroxaban will be provided to complete the full course of therapy. If a patient withdraws his/her consent prior to completion of the study, the appropriate course of blood clot prevention therapy will be prescribed by the study doctor. Upon completion of rivaroxaban therapy, all patients will be required to have final study procedures performed. Those patients who continue oral rivaroxaban after discharge from the subacute unit will be required to return for an office visit for final study procedures either at the time of completion of rivaroxaban therapy or at the surgical follow-up visit. Patients who have rivaroxaban discontinued prior to discharge from the subacute unit will have final study procedures completed at that time and a subsequent office visit will not be required. In all cases, the prescribed rivaroxaban therapy must have been completed prior to the time of the final visit. Safety evaluations at the final visit will include clinical laboratory blood tests, a physical examination, urine pregnancy test (if applicable), recording of any adverse events including details regarding any bleeding episodes or blood clot events, and assessment of the surgical wound. All patients will return any unused study medication and study participation will be complete. All patients will receive oral rivaroxaban 10mg daily. First dose of rivaroxaban will be given within 2 days after admission to the subacute unit, in the morning within 12 hrs (if 30mg twice a day) or 24 hours (if 40mg daily) of the enoxaparin dose. Patients will then continue to receive a daily 10 mg dose each morning. The total duration of combined therapy (enoxparin plus rivaroxaban) may not exceed 35 days for patients with total hip replacement or 14 days with total knee replacement.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Rivaroxaban 10mg tablet daily receiving the first dose within two days after admission to the subacute unit. The total duration of combined venous blood clot prevention therapy with enoxaparin and rivaroxaban may not exceed 35 days for patients with total hip replacement or 14 days with total knee replacement
Drug: Rivaroxaban
10mg tablet daily, receiving the first dose within two days after admission to the subacute unit. The total duration of combined venous blood clot prevention therapy with enoxaparin and rivaroxaban may not exceed 35 days for patients with total hip replacement or 14 days with total knee replacement
Summary of Change From Day 3 to Day 1 in Maximum Anti-Factor Xa (aFXa)
Descriptive statistics for per-patient maximum Anti-Factor Xa laboratory value selected from the 7 consecutive blood draws (0, 2, 4, 6, 8, 12 and 24 hrs post dose) on Day 1 and Day 3
Time frame: Day 1, Day 3
Summary of Change From Day 3 to Day 1 in Maximum Prothrombin Time
Descriptive statistics for per-patient maximum prothrombin time laboratory value selected from the 7 consecutive blood draws (0, 2, 4, 6, 8, 12 and 24 hrs post dose) on Day 1 and Day 3
Time frame: Day 1, Day 3
Summary of Change From Day 1 to Day 3 in Area Under the Curve (AUC) of aFXa
Descriptive statistics for Area Under the Curve (AUC) on Study Day 1 and Day 3 for Anti-Factor Xa, based on the 7 consecutive blood draws at 0, 2, 4, 6, 8, 12 and 24 hours post dose
Time frame: Day 1, Day 3
Summary of Change From Day 1 to Day 3 in AUC of Prothrombin Time
Descriptive statistics for AUC on Study Day 1 and Day 3 for prothrombin time, based on the 7 consecutive blood draws at 0, 2, 4, 6, 8, 12 and 24 hours post dose
Time frame: Day 1, Day 3
| Milestone | Rivaroxaban |
|---|---|
| Started | 53 |
| Completed | 46 |
| Not completed | 7 |
| Withdrew: Adverse event | 2 |
| Withdrew: Withdrawal by subject | 5 |
Descriptive statistics for per-patient maximum Anti-Factor Xa laboratory value selected from the 7 consecutive blood draws (0, 2, 4, 6, 8, 12 and 24 hrs post dose) on Day 1 and Day 3
| IU/ml | Rivaroxaban |
|---|---|
| Day 1 | 1.66 ± 0.422 |
| Day 3 | 1.83 ± 0.305 |
Descriptive statistics for per-patient maximum prothrombin time laboratory value selected from the 7 consecutive blood draws (0, 2, 4, 6, 8, 12 and 24 hrs post dose) on Day 1 and Day 3
| sec | Rivaroxaban |
|---|---|
| Day 1 | 21.57 ± 3.405 |
| Day 3 | 20.51 ± 3.179 |
Descriptive statistics for Area Under the Curve (AUC) on Study Day 1 and Day 3 for Anti-Factor Xa, based on the 7 consecutive blood draws at 0, 2, 4, 6, 8, 12 and 24 hours post dose
| IU/ml*hour | Rivaroxaban |
|---|---|
| Day 1 | 21.35 ± 7.086 |
| Day 3 | 20.74 ± 7.17 |
Descriptive statistics for AUC on Study Day 1 and Day 3 for prothrombin time, based on the 7 consecutive blood draws at 0, 2, 4, 6, 8, 12 and 24 hours post dose
| sec*hour | Rivaroxaban |
|---|---|
| Day 1 | 420.46 ± 44.361 |
| Day 3 | 391.37 ± 42.664 |
Collected over 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rivaroxaban | — | 3/53 (5.7%) | 38/53 (71.7%) |
| Event | Rivaroxaban |
|---|---|
| Arthritis InfectiveInfections and infestations | 1/53 |
| Lumbar Vertebral FractureInjury, poisoning and procedural complications | 1/53 |
| AnxietyPsychiatric disorders | 1/53 |
| Event | Rivaroxaban |
|---|---|
| ConstipationGastrointestinal disorders | 12/53 |
| NauseaGastrointestinal disorders | 9/53 |
| AstheniaGeneral disorders | 7/53 |
| PyrexiaGeneral disorders | 7/53 |
| Blood Iron DecreasedInvestigations | 5/53 |
| Muscle SpasmsMusculoskeletal and connective tissue disorders | 5/53 |
| InsomniaPsychiatric disorders | 5/53 |
| OedemaGeneral disorders | 4/53 |
| FallInjury, poisoning and procedural complications | 3/53 |
| TransfusionSurgical and medical procedures | 3/53 |
| Age, Categorical(Participants) | Rivaroxaban |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 12 |
| >=65 years | 41 |
| Age, Continuous(years) | Rivaroxaban |
|---|---|
| Mean | 70.5 ± 11.14 |
| Sex: Female, Male(Participants) | Rivaroxaban |
|---|---|
| Female | 29 |
| Male | 24 |
| Region of Enrollment(participants) | Rivaroxaban |
|---|---|
| UNITED STATES | 53 |
| Surgical Type(participants) | Rivaroxaban |
|---|---|
| Hip | 26 |
| Knee | 27 |
| Baseline BMI(kg/m^2) | Rivaroxaban |
|---|---|
| Mean | 29.5 ± 6.78 |
| Baseline Estimated Glomerular Filtration Rate (eGFR) From Local Lab(participants) | Rivaroxaban |
|---|---|
| eGFR >= 60 mL/min | 47 |
| eGFR Between 30 and 59 mL/min | 6 |
| Ethnicity(participants) | Rivaroxaban |
|---|---|
| Hispanic or Latino | 1 |
| Not Hispanic or Latino | 52 |
The record gives a start of Mar 2010, a primary completion of Dec 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2012, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rivaroxaban
Ortho-McNeil Janssen Scientific Affairs, LLC →